Momenta Pharmaceuticals Inc (MNTA)

19.00
0.00 (0.00)
NASDAQ : Health Care
Prev Close 19.00
Open 19.00
Day Low/High 18.60 / 19.25
52 Wk Low/High 7.86 / 23.62
Volume 416.72K
Avg Volume 622.50K
Exchange NASDAQ
Shares Outstanding 71.31M
Market Cap 1.35B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Mylan, Momenta Pharmaceuticals and Seres Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Interesting MNTA Put Options For February 2017

Interesting MNTA Put Options For February 2017

Investors in Momenta Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new February 2017 contracts and identified the following put contract of particular interest.

MNTA Crosses Above Average Analyst Target

MNTA Crosses Above Average Analyst Target

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $15.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.

Momenta Pharmaceuticals Announces Publication On The Design Of M230, A Novel Autoimmune Disease Drug Candidate, In Science Translational Medicine

Momenta Pharmaceuticals Announces Publication On The Design Of M230, A Novel Autoimmune Disease Drug Candidate, In Science Translational Medicine

Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio

Momenta Pharmaceuticals (MNTA) Stock Surges, Barclays Upgrades

Momenta Pharmaceuticals (MNTA) Stock Surges, Barclays Upgrades

Momenta Pharmaceuticals' (MNTA) stock rating was raised to 'overweight' at Barclays on Tuesday.

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.

Momenta Pharmaceuticals To Regain Global Development And Commercialization Rights To M923, A Proposed Biosimilar Of HUMIRA® (adalimumab), Through Termination Of Collaboration Agreement With Baxalta, Now Part Of Shire

Momenta Pharmaceuticals To Regain Global Development And Commercialization Rights To M923, A Proposed Biosimilar Of HUMIRA® (adalimumab), Through Termination Of Collaboration Agreement With Baxalta, Now Part Of Shire

Shire to continue to fund the M923 program for twelve months and will transfer all remaining clinical, regulatory and commercialization activities to Momenta

First Week of November 18th Options Trading For Momenta Pharmaceuticals (MNTA)

First Week of November 18th Options Trading For Momenta Pharmaceuticals (MNTA)

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Shark Bites: Energous, NeoPhotonics Top My Watch List

Shark Bites: Energous, NeoPhotonics Top My Watch List

The market action is solid today as my hunt for individual stock picks continues.

Bullish Two Hundred Day Moving Average Cross - MNTA

Bullish Two Hundred Day Moving Average Cross - MNTA

In trading on Friday, shares of Momenta Pharmaceuticals Inc crossed above their 200 day moving average of $12.28, changing hands as high as $12.83 per share. Momenta Pharmaceuticals Inc shares are currently trading up about 14.4% on the day.